+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Opioid Use Disorder"

From
Opioid Use Disorder Market Forecasts from 2023 to 2028 - Product Thumbnail Image

Opioid Use Disorder Market Forecasts from 2023 to 2028

  • Report
  • November 2023
  • 140 Pages
  • Global
From
Opioid Use Disorder (OUD) - Epidemiology Forecast - 2032 - Product Thumbnail Image

Opioid Use Disorder (OUD) - Epidemiology Forecast - 2032

  • Report
  • July 2023
  • 67 Pages
  • Global
From
From
From
Opioid Receptor Agonists - Pipeline Insight, 2024 - Product Thumbnail Image

Opioid Receptor Agonists - Pipeline Insight, 2024

  • Clinical Trials
  • January 2024
  • 90 Pages
  • Global
From
From
Opioid Drugs: Global Markets to 2023 - Product Thumbnail Image

Opioid Drugs: Global Markets to 2023

  • Report
  • November 2018
  • 147 Pages
  • Global
From
From
From
From
From
Loading Indicator

Opioid Use Disorder (OUD) is a type of addiction disorder that is characterized by the compulsive use of opioids, such as heroin, morphine, and prescription painkillers. OUD is a serious public health issue, with an estimated 2.1 million people in the United States suffering from the disorder. OUD is associated with a range of physical and psychological health problems, including an increased risk of overdose, infectious diseases, and mental health issues. Treatment for OUD typically involves a combination of medication-assisted treatment (MAT) and psychosocial interventions. MAT involves the use of medications, such as buprenorphine and methadone, to reduce cravings and withdrawal symptoms. Psychosocial interventions include cognitive-behavioral therapy, motivational interviewing, and 12-step programs. Companies in the OUD market include Indivior, Alkermes, Orexo, and Braeburn Pharmaceuticals. Show Less Read more